Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines

  ZUG, Switzerland - Thursday, 30. January 2025 AETOSWire 

New research shows that loose or sagging skin on the face and neck is most often noted after medication-driven weight loss, with facial changes typically observed 3-6 months following treatment (in 45% of respondents), and sometimes as early as 1-2 months (28%)1

In addition, more than 60% of those patients experiencing medication-driven weight loss show a strong interest in a dual-expertise service that integrates both medical and aesthetic professionals to support them during their weight loss journey1

At IMCAS, Galderma will further educate healthcare professionals on this topic by hosting a masterclass with international aesthetics experts who will delve into how to manage facial changes in patients experiencing medication-driven weight loss, in clinical practice

Additionally, the first international consensus-based guidelines by global experts for understanding and managing the unique aesthetic needs of this patient population, supported by Galderma, will be presented as part of a session dedicated to rapid facial volume loss2

 

(BUSINESS WIRE) -- Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient’s journey, as well as the first international consensus-based guidelines from global experts on how to treat this patient population.

Today, at the International Master Course on Aging Science (IMCAS) 2025 annual congress, Galderma will also host a first-of-its-kind masterclass on this topic with international aesthetics experts. Titled “Managing Facial Changes in Patients with Medication-Driven Weight-Loss”, the session will be the opportunity to discuss strategies for managing facial changes in this patient population in clinical practice.

While the rates and stages of adoption differ worldwide, the use of prescription weight loss medications is set to increase globally, with $100 billion sales globally forecasted by 2030, which will have a considerable impact on aesthetics for both patients and healthcare professionals3. With 62% of patients using glucagon-like peptide-1 (GLP-1) getting aesthetic treatment following a healthcare professional recommendation1, there is a clear need for guidance on how to treat this new patient population.

First international consensus-based guidelines

Recognizing the significance and broad impact of prescription weight loss medications, Galderma commissioned the Delphi study to address the need for high-quality research in this area and help establish clinical guidelines for identifying and managing the unique needs of this patient population. This international, multidisciplinary study — incorporating patient interviews, market research, literature reviews, and insights from global experts with extensive experience in treating medication-driven weight loss patients — culminated in a global consensus on key criteria, expert perspectives, and treatment prioritization, all supported by real-world case studies2. These novel consensus guidelines, submitted for publication as the first international consensus-based guidelines from global experts on how to treat this patient population, will be presented by Dr. Andreas Nikolis, during a focus session on “Rapid facial volume loss: causes and consequences” on January 31st, 2025 in the Grand Amphi.

Additionally, Galderma has surveyed more than 1,000 male and female respondents using weight loss medications, aged between 25-65 across the United States, Brazil, Europe and the Middle East1. The focus is understanding the anatomical and aesthetic impact of medication-driven weight loss on the skin, to help equip healthcare professionals to guide patients effectively along their weight loss and aesthetics journey, based on their unique needs.

 

“With 23% of patients who are already or plan to undergo specific aesthetic treatments, we are now witnessing the emergence of a distinct patient population — those who have undergone significant weight loss and are now seeking complementary aesthetic care. With unique needs, these patients require a thoughtful, integrated approach from healthcare providers. Galderma’s cutting-edge research plays a pivotal role in equipping healthcare providers with the knowledge they need to stay at the forefront of this shift. By addressing these patients' specific concerns from the outset, we can provide a more holistic, tailored approach that enhances both physical transformation and overall well-being.”

 

DR. ANDREAS NIKOLIS, M.D., PH.D., FRCSC,

BOARD-CERTIFIED PLASTIC SURGEON

MONTREAL, CANADA

 

 

Medication-driven weight loss can lead to a myriad of facial changes, from dry or dull skin to sagging and a gaunt, hollowed-out appearance, as well as alterations in facial structure and balance4. Nearly half (48%) of respondents report significant facial changes due to weight loss treatment1. Menopausal women, in particular, experience higher levels of sagging skin, a slimmer face, and less radiant skin1. Loose or sagging skin on the face and neck is often noted after some weight loss, with facial changes typically observed 3-6 months following treatment (45%), and sometimes as early as 1-2 months (28%)1. These changes occur for several reasons: the loss of fat that typically stretches and cushions the skin, contributing to a youthful appearance, can lead to volume depletion and sagging1. Additionally, the reduction of collagen, elastin, and other essential nutrients can affect skin quality, facial definition, and contouring1.

60% of aesthetic users have undergone treatments to address these effects, while one third of aesthetic considerers would have taken additional measures to prevent skin changes if they had known about the effects on the skin prior to starting their weight loss journey1. The data further reveals that a significant barrier to pursuing aesthetic treatments is the lack of education and information, affecting both current and potential aesthetic users, regardless of their geographical location or stage in the weight loss process1. Further, more than 60% of patients experiencing medicine-driven weight loss show a strong interest in a dual-expertise service that integrates medical and aesthetic professionals to support them during their journey1. These findings from Galderma’s research show that a new, holistic approach to weight loss planning could better support this specific patient population and the healthcare professionals who treat them.

 

“Galderma is committed to leading the way in understanding the impact of medication-driven weight loss on the skin. As the dermatology category leader, we know that this is not a one size fits all approach. With our deep skin knowledge, aesthetic expertise and individualized treatment approach, Galderma is uniquely positioned to support this evolution and help patients achieve the radiant glow and appearance that they desire.”

 

GERRY MUHLE

HEAD GLOBAL OF PRODUCT STRATEGY

GALDERMA

 

Specifically, 48% of respondents in the study reported that they would undergo Sculptra® treatment and 41% would undergo Restylane® treatment, to address the changes experienced on their face as a result of weight loss treatment1, demonstrating the need for different aesthetic treatments that address the impact on their skin throughout their weight loss journey.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

1 Galderma MAC Research. 2024

2 Nikolis A, Enright KM, Fabi S, Somenek M, Avelar L, Franco J, Haddad A, Angelo-Kathar M, Huang J, Safran T, Prygova I, Dayan S. Consensus statements on managing aesthetic needs in prescription medication-driven rapid weight loss patients: An international, multidisciplinary Delphi study. IMCAS 2025.

3 JP Morgan report. The increase in appetite for obesity drugs. November 2023

4 Humphrey CD, Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250129028652/en/

Permalink

https://www.aetoswire.com/en/news/3001202544343

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Sébastien Cros

Corporate Communications Director

sebastien.cros@galderma.com

+41 79 529 59 85

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

 

Brightcove Launches AI Content Suite, The First General Availability Release From Its Successful AI Pilot Program, To Maximize Content Creation and Production for Customers

  The new AI-driven solution empowers creators and marketers to increase productivity, create more impactful content, and extend global reach with minimal effort

(BUSINESS WIRE) -- Brightcove (NASDAQ: BCOV), the world’s most trusted intelligent video engagement platform company, announces the launch of its AI Content Suite, the company's first official general availability release following a successful customer pilot program in 2024. This innovative suite introduces a range of AI-powered tools to increase the impact of video content while also improving business productivity, making it a seamless and easy experience for content creators to get more from their content and drive greater engagement across their audiences.

The Brightcove AI Content Suite includes three AI-powered capabilities – content creation, metadata optimization, and translation – which simplify video content production by automating the creation and optimization processes.

"The AI Content Suite is a force multiplier for anyone looking to expand the impact of their video content without increasing their workload," said Scott Levine, Chief Product Officer at Brightcove. "Embedded within our video platform, the AI Content Suite easily and quickly enables a video creation multiplier effect without going to other tools and platforms. This allows our customers to maximize their content reach and engagement."

The AI Content Suite allows companies to harness the full potential of the video content they own with features including:

• Rapid, automated conversion of long-form content into engaging short-form clips, highlight reels, and theme-based chapters to maximize reach across channels

• Conversion of horizontal video content into vertical formats to extend engagement with mobile viewers and across social platforms

• Enhanced discoverability through auto-generated metadata (including titles, tags and descriptions), ensuring audiences find and engage with relevant content

• Universal translation capabilities to dozens of languages to extend global reach and make content more accessible (coming soon)

The Brightcove AI Content Suite is part of Brightcove’s broader AI product strategy and roadmap. It was built in close collaboration with customers across various industries to create solutions that address their business needs, such as deepening audience engagement and improving efficiencies in creating, editing and distributing video content.

"The AI Content Suite transformed our clip and trailer production process. What used to take hours now takes minutes, allowing us to reduce costs and focus more on creativity and strategy,” shared Remi Brunier, Director of Product and UX at STV, the most-watched peak-time channel in Scotland and home to some of the most popular shows on Scottish television. STV was one of the dozens of customers who participated in Brightcove’s AI pilot program. “By automating the creation of engaging, concise trailers for our content, we've scaled our production for a wider range of titles and significantly reduced costs. This shift has been critical for our business, allowing our team to focus on high-profile projects and enhance our presence on social media platforms.”

The Brightcove AI Suite will continue to launch new products based on customer feedback. These include the addition of text-to-video capabilities and AI-powered automated video interactivity, personalization, and recommendations to engage audiences and build loyalty.

Brightcove is committed to maintaining the highest security standards and ethical AI use. It ensures all tools in the AI Content Suite are backed by its robust security framework and the Brightcove AI Pledge. As part of this pledge, Brightcove will never use customers’ content or personal data to train AI models without their explicit consent.

For more information, visit Brightcove.com.

About Brightcove Inc.

Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X, Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250129442732/en/

Permalink
https://aetoswire.com/en/news/2901202544335

Contacts

Media Contacts:
Brightcove
press@brightcove.com

Thales Partners with the State of Georgia Department of Driver Services to Enhance Citizen Experience

 

 

• Thales Enrollment Kiosks for credential issuance help the U.S. Georgia Department of Driver Services (DDS) improve their customer experience by making common services more accessible and reducing wait times in their Customer Service Center (CSC).
• Citizens in Georgia may currently access DDS services (licenses renewal, change of address etc.) at 30 kiosks in 23 locations, with more kiosks expected throughout 2025.
• Featuring a user-friendly touch-screen interface and automatic height adjustment, these Kiosks provide a quick and easy experience for all citizens. Thales is the industry leader in this field, having implemented over 1,700 enrollment kiosks worldwide, applying a "security by design" approach.

 

(BUSINESS WIRE) -- Through a partnership with the Georgia Department of Driver Services (DDS), Thales has successfully deployed inclusively designed enrollment kiosks for credential issuance at Georgia DDS Customer Service Centers locations. This user-friendly solution is designed to enhance the customer experience and free up staff time, bringing a new level of efficiency and convenience to DDS centers across the state.

The Thales Enrollment Kiosks offer Georgia citizens a safe and convenient new option for a variety of DDS services, including license renewals, obtaining driving history reports, and change of address transactions. The 30 kiosks are strategically placed across the state at 23 high volume CSC locations, providing Georgians with a quick, easy, and hassle-free way to manage their licensing needs.

"The introduction of Thales Enrollment Kiosks for credential issuance has significantly enhanced the customer experience at the Georgia Department of Driver Services. The implementation of this technology has improved staffing efficiencies, enabling our team to focus on providing personalized assistance where it's most needed. Overall, the Thales Kiosks have been a game-changer for both our customers and our staff." – Spencer R. Moore, Commissioner for Georgia Department of Driver Services.

Georgia DDS has already seen improvements to their operational efficiency for driver services by using these new self-service kiosks, further enhancing the customer experience. With Thales Kiosk implementations, a single Georgia DDS staff member can simultaneously manage multiple kiosks, enabling DDS staff to provide customized support and manage more complex inquiries, ultimately providing a higher quality of service for their citizens.

"We are thrilled to partner with the Georgia Department of Driver Services to introduce our advanced Self-Service Kiosks," said Tyson Moler, Vice President for Thales Identity and Biometric Solutions in North America. "These Kiosks represent a significant leap forward in delivering secure, fast, efficient, and convenient services to the citizens of Georgia. By streamlining routine transactions, we are also helping Georgia DDS optimize their resources and focus on delivering exceptional customer service."

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener, and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

About Thales in the USA

In the United States, Thales has conducted significant research and development, manufacturing, and service capabilities for more than 130 years. Today, Thales has 37 locations around the U.S., employing nearly 5,000 people. Working closely with U.S. customers and local partners, Thales is able to meet the most complex requirements for every operating environment.

PLEASE VISIT

Thales Group

Download HD photos

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250129680944/en/

Permalink
https://aetoswire.com/en/news/2901202544322

Contacts

PRESS

Thales, Media Relations
North America
Jennifer Tumminio
jennifer.tumminio@thalesgroup.com

Wissam Jabre Joins NetApp as Executive Vice President and Chief Financial Officer

 (BUSINESS WIRE)--Today, NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, announced the appointment of Wissam Jabre as Executive Vice President and Chief Financial Officer effective March 10, 2025. Jabre brings over 20 years of experience leading finance organizations and a strong track record of value creation and disciplined operational management. Jabre’s appointment follows the previously announced planned retirement of Mike Berry, who served as NetApp’s Executive Vice President and Chief Financial Officer for the last five years.

“We are thrilled to welcome Wissam to our leadership team,” said George Kurian, Chief Executive Officer. “His decades of financial experience will be invaluable as we continue to execute on our visionary approach for a data-driven future. As a seasoned CFO and proven leader in building high-performance finance teams, Wissam will play a pivotal role working across the business to drive sustained growth and long-term value for our stakeholders.”

“I’m excited to join this incredible team as NetApp builds on its momentum and captures market share with its leading intelligent data infrastructure platform,” said Wissam Jabre, incoming Chief Financial Officer. “There is tremendous opportunity ahead to enhance value for our shareholders. I look forward to partnering with the leadership team and leading the finance organization as we build on the Company’s efforts to drive growth and profitability, as well as deliver results for our stakeholders.”

Jabre brings extensive experience leading finance organizations for businesses that move at the speed of customer requirements. He has most recently held the position of Executive Vice President and Chief Financial Officer at Western Digital Corporation, where he led the global finance organization, including accounting, financial reporting, tax, treasury, internal audit, and investor relations. He previously served as Senior Vice President and Chief Financial Officer of Dialog Semiconductor from 2016 until it was acquired by Renesas Electronics in 2021. Prior to that, he held senior finance roles at Advanced Micro Devices, Freescale Semiconductor, and Motorola. Jabre began his career with Schlumberger, where he held engineering and finance roles. He also sits on the board of MKS Instruments, Inc. where he is an audit committee member. Jabre holds an MBA from Columbia Business School and a B.E. in Electrical Engineering from the American University of Beirut.

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250128604636/en/

Permalink

https://www.aetoswire.com/en/news/54194188

Contacts

 

Media Contact

Kenya Hayes

NetApp

kenya.hayes@netapp.com

Investor Contact

Kris Newton

NetApp

kris.newton@netapp.com

 

Diatech Pharmacogenetics Expands Collaboration with Merck to Enhance Patient Access to Personalized Medicine in the Middle East and Africa

 

JESI, Italy - 

(BUSINESS WIRE) -- Diatech Pharmacogenetics announced an expansion of its collaboration with Merck Serono Middle East Ltd., affiliates of Merck KGaA (“Merck”). The collaboration aims to improve patient access to RAS biomarker testing in the Middle East and Africa (MEA) regions.

Colorectal cancer is the third most common cancer worldwide, accounting for approximately 10% of all cancer cases. Colon cancer is the second leading cause of cancer-related deaths worldwide1. In 2020, more than 1.9 million new cases of colorectal cancer and more than 930,000 deaths due to colorectal cancer were estimated to have occurred worldwide. Large geographical variations in incidence and mortality rates were observed. The incidence rates were highest in Europe, Australia and New Zealand, and the mortality rates were highest in Eastern Europe. By 2040 the burden of colorectal cancer will increase to 3.2 million new cases per year (an increase of 63%) and 1.6 million deaths per year (an increase of 73%).1

Targeted therapy, against cancer, may be used in combination with chemotherapy for patients with specific genetic mutations, such as KRAS, BRAF and NRAS mutations. Immunotherapy drugs may be considered for patients with tumors that exhibit specific genetic markers, such as microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR).1

The CE-IVD diagnostic solution offered by Diatech Pharmacogenetics™ can provide a quick, precise and accurate result on the status of biomarkers involved in colorectal cancer. The easy-to-install solution adapts to any environment, with a user-friendly dedicated analysis software.

Oliva Alberti, Chief Executive Officer of Diatech Pharmacogenetics, commented: “We are pleased to announce the expansion of our collaboration with Merck in the Middle East and Africa (MEA) regions, aimed at advancing healthcare solutions and ensuring timely, accurate genetic testing for mCRC patients. As part of our mission to enable global access to personalized medicine, Diatech Pharmacogenetics is proud to offer the innovative technology for colorectal cancer genetic testing across countries in the MEA region. This partnership highlights our joint commitment to addressing the challenges of the healthcare landscape in the MEA region and ensuring that patients receive the right treatment at the right time.”

Ramsey Morad, SVP & Head MEAR - Middle East, Africa, Turkey & Russia/CIS at Merck, commented: “At Merck, we are dedicated to enhancing patient care and access to innovative solutions. This expanded collaboration with Diatech Pharmacogenetics underscores our commitment to improving RAS biomarker testing in the Middle East and Africa. By working together, we aim to empower healthcare providers with the tools necessary to deliver personalized treatment options for colorectal cancer patients, ultimately contributing to better health outcomes in the region.”

Note

www.who.int

More information: www.diatechpharmacogenetics.com

About Diatech Pharmacogenetics

Diatech Pharmacogenetics, the Italian Company, leader in molecular tests for cancer precision medicine has more than 25 years of expertise in the molecular diagnostics market alongside rapid worldwide growth with over 1 billion diagnostic tests sold. The company’s mission is to research and produce revolutionary CE-IVD solutions dedicated to democratizing molecular oncology for solid tumors and blood cancers. Diatech has shown strong growth in recent years and today is among the first players in the EU market for the oncology diagnostic market.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250129995537/en/

Permalink

https://www.aetoswire.com/en/news/2901202544314

Contacts

Maria Luisa Biondi - Diatech Pharmacogenetics

MariaLuisa.Biondi@diatechpharmacogenetics.com

 

Supreme Court Sanctions Agreement for FTX DM Joint Official Liquidators to Subordinate Securities Commission of The Bahamas’ $221.55 Million Regulatory Penalties Claim

 NASSAU, The Bahamas - Thursday, 30. January 2025

(BUSINESS WIRE) -- The Supreme Court of The Bahamas today approved an agreement for the Joint Official Liquidators (JOLs) of FTX Digital Markets Ltd. (FTX DM) to subordinate the Securities Commission of The Bahamas’ (the Commission) $221.55 million regulatory claim against FTX DM.

The Court-approved “Claim Subordination Agreement” between the JOLs and the Commission enables the reprioritisation of the payment of all customers and other creditors of FTX DM, including any interest due to FTX DM customers, ahead of the Commission’s “Allowed Regulatory Claim”.

The JOLs’ request was based on its powers to enter into agreements and perform its obligations pursuant to the Amended Global Settlement Agreement (GSA), dated 12 August 2024. Justice L Klein sanctioned the agreement between the JOLs and the Commission on 29 January 2025.

The Commission’s regulatory claim for penalties against FTX DM was for breaches of the Digital Assets and Registered Exchanges Act and the Financial Transactions Reporting Act, pursuant to investigations by the digital assets regulator.

Editor’s Information:

The Securities Commission of The Bahamas is a statutory body established in 1995. It is responsible for the regulation of securities, investment funds and the capital markets, financial and corporate service providers, digital assets and exchanges, and carbon credit trading.

The Digital Assets and Registered Exchanges Act, 2024 came into effect in July 2024, updating and expanding the digital asset legislative and regulatory frameworks. More information can be found at: DARE Act 2024 Information - Securities Commission of The Bahamas.

More information about the Securities Commission of The Bahamas can be found at: https://www.scb.gov.bs/.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250129890200/en/

Permalink

https://www.aetoswire.com/en/news/3001202544338

Contacts

Executive Director

Christina Rolle

242-397-4100

UN Tourism in Morocco: Driving Investments and Celebrating Innovation in Africa’s Most-Visited Destination

RABAT, Morocco - Wednesday, 29. January 2025 AETOSWire

(BUSINESS WIRE) -- UN Tourism has strengthened its partnership with the Kingdom of Morocco, a key ally in its mission to grow innovation across Africa and boost investments into the tourism sector of the region.

In an official visit to the Kingdom, UN Tourism Secretary-General Zurab Pololikashvili celebrated its achievements in growing tourism and making the sector a pillar of economic diversification and sustainable growth. According to the latest UN Tourism data, Morocco welcomed 17.4 million international tourists in 2024, a 20% increase on 2023, making it the most-visited country in all of Africa.

Investment Guidelines for Morocco launched
To support the further growth of tourism across the Kingdom, in Rabat, UN Tourism officially launched “Tourism Doing Business – Investing in Morocco”. The Guidelines – the latest in a growing portfolio of expert publications – outline the opportunities to be found in the tourism sector for international investors of all sizes. The Guidelines also set out investment trends and key areas of growth, including a focus on the Kingdom’s booming innovation ecosystem.

Supporting Moroccan tourism innovation

In Rabat, UN Tourism welcomed private sector leaders, including from SMIT Morocco, as well as leading entrepreneurs and small-business owners to celebrate innovation in the Kingdom’s tourism sector. In a keynote speech: “Global Trends on Tourism Tech and Innovation”, UN Tourism Executive Director Natalia Bayona highlighted the accelerating digital transformation of the sector.

Executive Director Bayona said: “Morocco's tourism sector has become a key economic driver, contributing 7.3% to GDP by 2023. With a remarkable 35% increase in international arrivals since 2019 and USD 10.5 billion in tourism revenue, Morocco is prepared to continue its growth. The country's stable political climate and strategic economic policies fortify this success."

Fatim-Zahra Ammor, Minister of Tourism Handicrafts and Social and Solidarity Economy, adds: "The Kingdom of Morocco's political stability, its competitive edge, the openness of its economy, the view on innovation and its forward thinking investment policies collectively positions the country as a privileged destination for both national and international investors”.

As part of the visit, an agreement was also signed to establish the UN Tourism Thematic Office for Africa, furthering Morocco’s role as a key partner in supporting tourism growth across the continent.

Top Start-ups recognized

The National Tourism Startup Competition, an initiative focused on fostering innovation in the Moroccan tourism sector and supported by the Moroccan Agency for Tourism Development (SMIT), has successfully concluded with the participation of 137 aspiring startups.

Among these, five standout enterprises were recognized for their groundbreaking contributions. Leading the charge is Ecodome, securing first place for its innovative approach to sustainable tourism. In a tie for second place, ATAR and Pikala showcased exceptional potential with their unique offerings. Taking the third spot is Wanaut, noted for its creative solutions in enhancing travel experiences. Finally, Mouja claimed fourth place, impressing judges with its forward-thinking strategies. This competition highlights Morocco's commitment to nurturing entrepreneurial talent and advancing its tourism industry through strategic investments and support.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250129432995/en/

Permalink
https://www.aetoswire.com/en/news/2901202544312

Contacts

claudia.safont@tinkle.es // +34.607408717